Sanofi and Regeneron's I-O med Libtayo, on a roll, puts up basal cell carcinoma win

Call it Libtayo’s month. After last week posting key data that could help it enter the lucrative non-small cell lung cancer market, the Sanofi and Regeneron immuno-oncology drug has rung up a win in advanced basal cell carcinoma.